Clinical trial · Observational
Elements of Adaptive Immunity in Epithelial Ovarian Cancer
Prognostic Significance of Adaptive Immunity Cell Infiltrates in the Microenvironment of High-grade Serous Ovarian Cancer
NCT07528911CI-TRIAL-00119496completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with carboplatin/paclitaxel chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial High Grade Serous Ovarian Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Assessment of elements of adaptive immunity in tumor biopsies | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with high grade serous ovarian cancer treated with chemotherapy
- interventionNames
- Other: Assessment of elements of adaptive immunity in tumor biopsies
Primary outcomes (1)
- measure
- Assessment of: Tertiary Lymphoid Structures (presence, absence) in tumor biopsies
- timeFrame
- through study completion, an average of 3 years
Secondary outcomes (4)
- measure
- Plasma cells (4-tiered score)
- timeFrame
- 3- years time frame (upon study completion)
- measure
- PD-L1 score (TPS score) in tumor biopsies
- timeFrame
- upon study completion (3 years)
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy Exclusion Criteria: * Any other histology than high grade ovarian cancer * Patients with stages I-II (based on FIGO staging)
References
Publications (0)
Data not yet available
No reference posted for this study.